Biotechnology Division, Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran.
Vet Res Commun. 2024 Aug;48(4):2051-2068. doi: 10.1007/s11259-024-10432-x. Epub 2024 Jun 13.
The single variable domains of camelid heavy-chain only antibodies, known as nanobodies, have taken a long journey since their discovery in 1989 until the first nanobody-based drug's entrance to the market in 2022. On account of their unique properties, nanobodies have been successfully used for diagnosis and therapy against various diseases or conditions. Although research on the application of recombinant antibodies has focused on human medicine, the development of nanobodies has paved the way for incorporating recombinant antibody production in favour of veterinary medicine. Currently, despite many efforts in developing these biomolecules with diversified applications, significant opportunities exist for exploiting these highly versatile and cost-effective antibodies in veterinary medicine. The present study attempts to identify existing gaps and shed light on paths for future research by presenting an updated review on camelid nanobodies with potential applications in veterinary medicine.
单域骆驼重链抗体，即纳米抗体，自 1989 年被发现以来，历经多年发展，于 2022 年首款纳米抗体药物成功上市。纳米抗体因其独特的性质，已被成功用于多种疾病的诊断和治疗。虽然重组抗体的应用研究主要集中在人类医学领域，但纳米抗体的发展为在兽医领域引入重组抗体生产铺平了道路。目前，尽管人们在开发具有多样化应用的这些生物分子方面做出了许多努力，但在兽医领域利用这些高度多功能且具有成本效益的抗体仍具有巨大的潜力。本研究通过对在兽医领域具有潜在应用的纳米抗体进行综述，试图找出现有差距，并为未来研究指明方向。
